share_log

ZyVersa Therapeutics | DEFA14A: Others

ZyVersa Therapeutics | DEFA14A: Others

ZyVersa Therapeutics | DEFA14A:其他
SEC announcement ·  03/27 17:05
Moomoo AI 已提取核心信息
ZyVersa Therapeutics, Inc. has announced that starting March 27, 2024, Morrow Sodali LLC, the company's proxy solicitors, will disseminate an audio recording from the Chief Financial Officer, Peter Wolfe, to certain stockholders. The communication is part of the preparations for the upcoming 2024 Special Meeting of Stockholders scheduled for April 17, 2024. In the recording, Wolfe discusses the current biotech environment, characterized by low valuations and reduced capital availability, and outlines the company's strategy to navigate these challenges. One of the strategies mentioned is a potential reverse stock split to maintain compliance with Nasdaq's listing requirements and to make the stock more attractive to new investors. However, Wolfe expresses hope that this measure will not be necessary, citing increased investor confidence due...Show More
ZyVersa Therapeutics, Inc. has announced that starting March 27, 2024, Morrow Sodali LLC, the company's proxy solicitors, will disseminate an audio recording from the Chief Financial Officer, Peter Wolfe, to certain stockholders. The communication is part of the preparations for the upcoming 2024 Special Meeting of Stockholders scheduled for April 17, 2024. In the recording, Wolfe discusses the current biotech environment, characterized by low valuations and reduced capital availability, and outlines the company's strategy to navigate these challenges. One of the strategies mentioned is a potential reverse stock split to maintain compliance with Nasdaq's listing requirements and to make the stock more attractive to new investors. However, Wolfe expresses hope that this measure will not be necessary, citing increased investor confidence due to anticipated milestones for the company's lead drugs targeting kidney and inflammatory diseases. Shareholders are urged to vote in favor of the reverse stock split proposal during the virtual Special Meeting, with proxy materials and voting instructions to be mailed to them. The company emphasizes the importance of shareholder votes and appreciates their ongoing support.
ZyVersa Therapeutics, Inc.宣布,从2024年3月27日起,该公司的代理律师Morrow Sodali LLC将向某些股东传播首席财务官彼得·沃尔夫的录音。该通报是定于2024年4月17日举行的2024年股东特别会议筹备工作的一部分。在录音中,沃尔夫讨论了当前以低估值和资本可用性减少为特征的生物技术环境,并概述了公司应对这些挑战的战略。提到的策略之一是可能进行反向股票拆分,以保持对纳斯达克上市要求的合规性,并使股票对新投资者更具吸引力。但是,沃尔夫表示希望没有必要采取这项措施,理由是该公司针对肾脏和炎症性疾病的主要药物预计将出现里程碑,投资者信心增强。敦促股东在虚拟特别会议期间对反向股票拆分提案投赞成票,并将代理材料和投票说明邮寄给他们。该公司强调股东投票的重要性,并感谢他们的持续支持。
ZyVersa Therapeutics, Inc.宣布,从2024年3月27日起,该公司的代理律师Morrow Sodali LLC将向某些股东传播首席财务官彼得·沃尔夫的录音。该通报是定于2024年4月17日举行的2024年股东特别会议筹备工作的一部分。在录音中,沃尔夫讨论了当前以低估值和资本可用性减少为特征的生物技术环境,并概述了公司应对这些挑战的战略。提到的策略之一是可能进行反向股票拆分,以保持对纳斯达克上市要求的合规性,并使股票对新投资者更具吸引力。但是,沃尔夫表示希望没有必要采取这项措施,理由是该公司针对肾脏和炎症性疾病的主要药物预计将出现里程碑,投资者信心增强。敦促股东在虚拟特别会议期间对反向股票拆分提案投赞成票,并将代理材料和投票说明邮寄给他们。该公司强调股东投票的重要性,并感谢他们的持续支持。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息